

IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE


VOL 20 NO 1 MAR 2003

ISSN 0790-9667



'The Good Grey Morning' by Jack B Yeats (oil on canvas, 49 x 67cm)

From an exhibition at the Irish Museum of Modern Art, Royal Hospital Kilmainham, Dublin 8.



See the difference

Abbreviated Prescribing Information for Geodon (ziprasidone). Republic of Ireland Geodon™. Presentation: Capsules containing ziprasidone hydrochloride monohydrate equivalent to 20, 40, 60 and 80mg ziprasidone. Indications: Treatment of schizophrenia Dosage: Acute treatment - 40mg twice daily with food. Maximum dosage of 80mg twice daily may be reached by day 3 of treatment. Maintenance treatment - use the lowest effective dose. In elderly: A lower starting dose should be considered for patients over 65 where clinical factors warrant. In children: Caution as no evaluation under 18 years of age. In renal impairment: No dosage adjustment required. In hepatic impairment: Consider lower doses in hepatic insufficiency. Caution in severe hepatic insufficiency. Contra-indications: Known hypersensitivity to any ingredient of the product. Known QT-interval prolongation. Congenital long QT syndrome. Recent acute myocardial infarction. Uncompensated heart failure. Arrhythmias treated with class IA and III antiarrhythmic drugs. Concomitant treatment with medicines known to prolong the QT interval. Special warnings: A medical history, family history and physical examination should be undertaken to identify patients for whom ziprasidone is not recommended. Mild to moderate dose-related QT-interval prolongation, therefore, do not give together with medicinal products known to prolong the QT interval. Caution in patients with significant bradycardia. Before treatment is started - correct electrolyte disturbances; and as with other drugs which prolong QT interval, consider ECG review in patients with stable cardiac disease. If cardiac symptoms occur, consider the possibility of a malignant cardiac arrhythmia and perform a cardiac evaluation, including an ECG. It is recommended to stop treatment if the QT interval is >500msec. No cases of Neuroleptic Malignant Syndrome (NMS) seen in clinical trials, but potential risk cannot be excluded. Management of NMS should include immediate withdrawal of all antipsychotic drugs. Potential to cause tardive dyskinesia, if signs appear consider dose reduction or discontinuation. Caution in patients with a history of seizures. Interactions: ziprasidone should not be given with medicinal products known to prolong the QT interval (see SPC for details). Caution in combination with other centrally acting drugs and alcohol. Ziprasidone is unlikely to cause clinically important drug interactions mediated by CYP3A4 or CYP2D6 (see SPC for details). Pregnancy and lactation: Not recommended unless the expected benefit outweighs the risk. Women of childbearing potential should use an appropriate method of contraception. Avoid breastfeeding. Driving: Ziprasidone may cause somnolence, therefore caution patients likely to drive or operate machines. Undesirable effects: In short term placebo controlled trials: >1/10 somnolence; >1/100, <1/10 asthenia, headache, constipation, dry mouth, dyspepsia, increased salivation, nausea, vomiting, agitation, akathisia, dizziness, dystonia, extrapyramidal syndrome, hypertonia, tremor, abnormal vision; >1/1000, <1/100 pain, postural hypotension, tachycardia, flatulence, thirst, joint disorder, leg cramps, cogwheel rigidity, paresthesia, speech disorder, tardive dyskinesia, rhinitis, rash, urticaria. In long term maintenance trials: elevated prolactin levels, returning to normal without cessation of treatment and rare reports of clinical manifestation (gynaecomastia and breast enlargement). Legal Category: POM. Package quantities: blister packs containing 56 capsules. Further information on request: Pfizer (Ireland) Limited, Parkway House, Ballymount Road Lower, Dublin 12, Republic of Ireland. Marketing Authorisation numbers: PA 19/52/5. Date of first authorisation/renewal of the authorisation: February 2002. Date of revision of the text: February 2002.

MAKE THE SWITCH

NEW GEODON™

(ziprasidone HCl)

See the difference

Editor-in-Chief: Brian Lawlor

Production Editor:

Anne Henriksen

Advertising Manager:

Helen Martin

Administrator:

Andrea McAdam

Founding Editor: Mark Hartman

Associate Editors:

Ted Dinan (Cork), David King (Belfast)

Editorial Board: Ken Brown (Belfast),

Patricia Casey (Dublin), Anthony Clare (Dublin), Stephen Cooper (Belfast), Thomas Fahy (Galway), Michael Fitzgerald (Dublin), Brian Leonard (Galway), Roy McClelland (Belfast), Aidan McGennis (Dublin), Ciaran O'Boyle (Dublin), Eadbhard O'Callaghan (Dublin), Art O'Connor (Dublin), Ethna O'Gorman (Belfast), Brian O'Shea (Wicklow), Ian Pullen (Edinburgh), David Sheehan (Tampa), Philip Snaith (Leeds), Hugh Staunton (Dublin), John Waddington (Dublin), Richard Williams (Victoria)

Statistical Editor:

Ronan Conroy (Dublin)

Submissions & correspondence to:

The Editor,
Irish Journal of Psychological Medicine,
25 Adelaide Street,
Dun Laoghaire,
Co Dublin, Ireland.

Telephone: 00-353-1-2803967

Fax: 00-353-1-2807076

Email: psychological@medmedia.ie

Website: www.ijpm.org

Publisher

MedMedia Ltd.
25 Adelaide Street, Dun Laoghaire,
Co Dublin, Ireland.

Printing: W&G Bairds Ltd

Subscriptions

Rates per volume of four issues
(Mar, Jun, Sept, Dec) Price Regions:
EU countries: €107, Stg65
Rest of World: €126, \$111
Incl. airmail postage internationally.

**Subscription enquiries, orders
and cheques made payable to:**

Turpin Distribution Service Ltd
Blackhorse Road, Letchworth
SG6 1HN, England.
Tel: +44 01462 672555
Fax: +44 01462 480947
Email: CustServTurpin@turpinltd.com
www.turpin-distribution.com

Circulation

2,200 to 54 countries.
The Journal participates in the World Health Organisation project to improve distribution of scientific materials on mental health. Publication does not imply endorsement. Limited photocopying authorisation granted for a fee to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA, or to appropriate Reproduction Rights Organisation; isolated non-profit, academic photocopying excepted.

Editorial

4 Managing sex offenders: is there a role for psychiatry?

Pat Gibbons

Original Papers

6 Eye movements and neurocognitive function in treatment resistant schizophrenia: a pilot study

Annette Thampi, Clarke Campbell, Mary Clarke, Suzanne Barrett, David J King

11 Home-base treatment in Monaghan: the first two years

MacDara McCauley, Siobhan Rooney, Ciaran Clarke, Teresa Carey, John Owens

Brief reports

15 Self-poisoning patients in the general hospital: the frequency and nature of their consultations with the general practitioner

S Masood-ul Hasan, David Owens

Review

18 Pharmacological management of treatment resistant depression: a clinical review

Noel Kennedy, Michael McDonough

Perspective

24 Antipsychotic drugs: atypical advantages and typical disadvantages

Padraig Wright, Luke O'Flaherty

Historical

28 Did Alan Turing have Asperger's syndrome?

Henry O'Connell, Michael Fitzgerald

Case reports

32 Deterioration in renal functioning following commencement on citalopram

Neil Mayfield, Kay Anderson, Colin Rodger

33 Catastrophic reaction following the separation of adult twins

Caroline Dunlop, Kelwyn Williams, Amy Holloway

35 Complex partial seizures presenting as frontotemporal dementia: a case report

Ray Goggins

5a Guidelines for Authors

19a John Dunne Medal

31 Obituary

36a Subscriptions


Indexed and abstracted by BIOLOGICAL ABSTRACTS (BIOSIS Previews); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE/INIST: PASCAL; EXCERPTA MEDICA/EMBASE; INSTITUTE FOR SCIENTIFIC INFORMATION: CURRENT CONTENTS/ Social & Behavioural Sciences (Social Science CITATION INDEX, Research Alert); PSYCHOLOGICAL ABSTRACTS (PsycINFO/PsycLIT); Cumulative Index to Nursing & Allied Health Literature, Current AIDS Literature (CAB Abstracts), International Pharmaceutical Abstracts, Linguistics & Language Behaviour Abstracts, Nutrition Abstracts and Reviews, (CAB Abstracts), Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, Sociological Abstracts.

Microfilm, microfiche & article copies from University Microfilms International, 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the Adonis service, whereby article copies can be printed out from compact disks (CD-ROM) on demand; explanatory leaflet available from ADONIS BV, PO Box 639, 1000 AV Amsterdam, The Netherlands. Journal listed in Ulrich's International Periodicals Directory (Bowker International Serials Database), EBSCO's Selected Periodicals for the Medical and Health Sciences, & EBSCO's Librarians' Handbook.

In Depression & Anxiety...



... Patients Get Better and Stay Better with



LUSTRALTM 50^{MG}
sertraline



Abbreviated Information: LUSTRALTM (sertraline) **Presentation:** Tablets containing 50mg or 100mg sertraline. **Indications:** Treatment of symptoms of depressive illness, including accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes, including accompanying symptoms of anxiety. Obsessive compulsive disorder (OCD) in adults and children. Panic disorder, with or without agoraphobia. Post-traumatic stress disorder (PTSD). **Dosage:** Lustral should be given as a single daily dose. The initial dose in depression and OCD is 50mg and the usual antidepressant dose is 50mg. The initial dose in panic disorder and PTSD is 25mg, increasing to 50mg after one week. Dosage can be further increased, if appropriate, to a more frequently than once per week given the 24 hour elimination half life of sertraline. Patients should be maintained on the lowest

effective dose. **Use in children (OCD only):** Ages 6-12: The initial dose is 25 mg/day increasing to 50 mg/day after 1 week. **Ages 13-17:** Usual adult dose. Consider generally lower body weights of children to avoid overdosing. Do not increase doses at intervals of less than 1 week. **Use in the elderly:** Usual adult dose. **Contra-indications:** Hypersensitivity to this group of drugs. Hepatic insufficiency, unstable epilepsy and convulsant disorders, pregnancy and lactation. Do not use with, or within two weeks of ending treatment with, MAOIs. At least 14 days should elapse before starting any MAOI following discontinuation of Lustral. **Precautions, warnings:** Renal insufficiency, ECT, epilepsy, driving. Lustral should be discontinued in a patient who develops seizures. Lustral should not be administered with benzodiazepines or other tranquilizers in patients who drive or operate machinery. Serotonergic drugs such as tryptophan or fenfluramine should be used with caution. Patients with a history of seizures should be monitored for an attempt or activation of mania/typomania. **Drug Interactions:** Caution with other centrally active medication. Lithium levels should be

monitored. Although Lustral has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. The potential for Lustral to interact with other highly protein bound drugs should be borne in mind. Interactions with e.g. warfarin, diazepam, tolbutamide and cimetidine have not been fully assessed. With warfarin prothrombin time should be monitored when Lustral is initiated or stopped. **Side-Effects:** Dry mouth, nausea, diarrhoea/loose stools, ejaculatory delay, tremor, increased sweating, dizziness, insomnia, somnolence, headache, anorexia and dyspepsia. Rarely, abnormal LFTs, hyponatraemia. Additionally agitation and hyperkinesia in paediatric OCD patients. The following have been reported with Lustral but may have no causal relationship: vomiting, abdominal pain, movement disorders, convulsions, menstrual irregularities, hyperprolactinaemia, galactorrhoea, rash and alopecia. Rarely, pancreatitis, serious liver events, altered platelet function, abnormal bleeding and purpura. As with other serotonin re-uptake inhibitors rare reports of agitation, confusion, depersonalisation, hallucinations, nervousness, postural

hypotension, hypo/hypertension, tachycardia and arrhythmias. Withdrawal reactions have been reported with Lustral. Common symptoms include dizziness, paraesthesia, headache, anxiety and nausea. Abrupt discontinuation of treatment with Lustral should be avoided. The majority of symptoms experienced on withdrawal of Lustral are non-serious and self-limiting. **Legal Category:** S1A. **Package Quantities:** 50mg tablet (PA 822/1/4) Calendar pack of 28; 100mg tablet (PA 822/1/5) Calendar pack of 28. **Product Authorisation Holder:** Pfizer (Ireland) Limited, Parkway House, Ballymount Road Lower, Dublin 12, Republic of Ireland. **Further information on request:** Pfizer (Ireland) Limited. **Date last revised:** February 2002

